Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

<div>Timeline with the estimated glomerular filtration rate (eGFR) and diameters of target lymph nodal metastases.</div>

Case Reports in Oncological Medicine

fig1

Figure 1

Figure 1: Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 

Figure 1 | Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 